Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales
1. Ionis posted a Q4 EPS loss of $0.66, beating expectations. 2. Quarterly sales were $227 million, exceeding consensus estimates. 3. 2024 revenue forecast of $705 million, surpassed guidance significantly. 4. Ionis launched Tryngolza, marking a key transition for the company. 5. CEO cites plans for three more drug launches within three years.